Novartis AG beats Q2 2025 expectations, but patent expiries and policy risks loom. Click for my updated look at NVS earnings ...

Johnson & Johnson shows steady growth in Q2, driven by medtech and oncology, yet talc litigation overshadows. Click for my ...

Pfizer faces a $1 billion sales hit in 2025 from IRA reforms, flat EPS and revenue forecasts, and long-term risks tied to patent expirations.

M Company (MMM) reports better-than-expected Q2 2025 results, raises full-year guidance, driven by growth in all business ...

Pfizer PFE is one of the biggest players in the oncology space — a position it strengthened with the 2023 acquisition of Seagen. The deal added four antibody-drug conjugates (ADC) — Adcetris, Padcev, ...

Strength, Questions and 2025 Outlook ...

American Express stock has been stable but unspectacular this year, staying in lockstep with the broader market. With ...

Morgan Stanley (NYSE:MS) has seen a notable shift in its stock ownership as Massachusetts Financial Services Co. MA reduced ...

Welcome to our live ASX coverage for Thursday, July 17. We’re excited to be trialing this new format. Expect a high volume of ...